Abbott Laboratories (ABT) stock has slipped roughly 13% year-to-date, a pullback that has caught the attention of income-focused investors. The healthcare giant has a record of more than five decades of dividend growth and continues to post steady business expansion across several segments. With a forward dividend yield of about 2.2%, compared to the healthcare sector average of roughly 1.6%, Abbott may be appealing to passive income investors looking for stability in this volatile market.
So, does this dip represent a buying opportunity?
